CIAS
BIO icon

Capital Investment Advisory Services’s Bio-Rad Laboratories Class A BIO Stock Holding History

Capital Investment Advisory Services’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-153
Closed -$51K – 623
2019
Q3 		$51K Hold
153
– – 0.01% 563
2019
Q2 		$48K Buy
+153
New +$45.8K 0.01% 560

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital Investment Advisory Services's BIO Position: Q4 2019 in Review

Capital Investment Advisory Services sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2019, closing a stake of 153 shares — an estimated $51K sold.

Capital Investment Advisory Services first reported a position in BIO in Q2 2019 and held it in 2 quarters. The position peaked at $51K in Q3 2019. 386 funds tracked by Wall St. Rank hold BIO as of Q4 2019.

  • Capital Investment Advisory Services reported no remaining Bio-Rad Laboratories Class A position as of Q4 2019 after selling out during the quarter.
  • Capital Investment Advisory Services sold 153 Bio-Rad Laboratories Class A shares in Q4 2019, an estimated $51K.
  • Capital Investment Advisory Services first reported a position in Bio-Rad Laboratories Class A in Q2 2019 and held it in 2 quarters.
  • Capital Investment Advisory Services's Bio-Rad Laboratories Class A position peaked at $51K in Q3 2019.
  • 386 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2019.

Based on Capital Investment Advisory Services's 13F filing for Q4 2019, filed 4 Feb 2020.